<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04020523</url>
  </required_header>
  <id_info>
    <org_study_id>K180603J</org_study_id>
    <secondary_id>2018-A01647-48</secondary_id>
    <nct_id>NCT04020523</nct_id>
  </id_info>
  <brief_title>Advanced MR Techniques for Breast Cancer Detection</brief_title>
  <acronym>RAPIDIRM</acronym>
  <official_title>Evaluation of Advanced MRI Acquisition Techniques for Perfusion and Diffusion to Detect Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GE Healthcare</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of advanced MRI acquisition techniques (perfusion and diffusion) to detect breast&#xD;
      cancer. Two MR advanced sequences will be added to a standard breast MRI protocol for&#xD;
      evaluation purpose.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective monocentric longitudinal study on a consecutive population of patients&#xD;
      who require breast MRI as part of their course of care in the radiology department of the&#xD;
      Tenon Hospital (3T MRI).&#xD;
&#xD;
      The standard protocol for breast MRI routinely performed in Tenon hospital consists of a set&#xD;
      of MR acquisitions performed with contrast agent injection. The research consists of adding&#xD;
      perfusion and diffusion sequences to the regular MR protocol. The addition of these sequences&#xD;
      does not require a new injection of contrast medium.&#xD;
&#xD;
      Diagnosis of lesions after the breast MR exam will be performed using standard MR sequences&#xD;
      as usual. According to the recommendations of SIFEM, the final diagnosis of the lesions will&#xD;
      be made either by histological analysis of a biopsy performed as part of the patient's&#xD;
      standard care pathway, or during patient's follow-up if a biopsy is not indicated (up to two&#xD;
      years after breast MR exam).&#xD;
&#xD;
      The research will focus on evaluating the sensitivity and specificity of perfusion MRI&#xD;
      sequence with or without diffusion MRI sequence compared to the sensitivity and specificity&#xD;
      of the standard protocol.&#xD;
&#xD;
      For the perfusion sequence, the following data will be extracted: qualitative (shape of the&#xD;
      contrast curve), semi-quantitative (elevation slope and asymptote of the curve) and&#xD;
      quantitative by compartmental modeling (tissue perfusion, blood volume fraction, surface&#xD;
      capillary permeability).&#xD;
&#xD;
      For the diffusion MRI, the extraction of quantitative data such as CDA, IVIM and Kurtosis&#xD;
      will be performed and parametric maps, cellularity maps and an assessment of lesion&#xD;
      heterogeneity will be calculated.&#xD;
&#xD;
      A correlation will be made with histological, immunohistochemical and molecular results of&#xD;
      cancers following biopsy&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Delayed start due to technical problems as well as the covid pandemic. Decision of the&#xD;
    investigator&#xD;
  </why_stopped>
  <start_date type="Anticipated">July 2019</start_date>
  <completion_date type="Anticipated">July 2024</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mammary lesions Visualization on ultrafast injected dynamic MRI: Yes/No</measure>
    <time_frame>Day 1 at inclusion</time_frame>
    <description>to evaluate whether ultrafast injected dynamic breast MRI, coupled or not with a diffusion sequence, allows to improve the specificity of standard MRI while maintaining the same sensitivity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mammary lesions Visualization with a diffusion sequence</measure>
    <time_frame>Day 1 at inclusion</time_frame>
    <description>to evaluate whether ultrafast injected dynamic breast MRI, coupled or not with a diffusion sequence, allows to improve the specificity of standard MRI while maintaining the same sensitivity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quantitative perfusion parameters : Enhancement Integral (EI (%))</measure>
    <time_frame>Day 1 at inclusion</time_frame>
    <description>Correlate the parameters of perfusion MR sequence with the markers immunochemicals of tumor angiogenesis on anatomopathological specimen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitative perfusion parameters : Maximum Slope of Increase (MSI (%/sec))</measure>
    <time_frame>Day 1 at inclusion</time_frame>
    <description>Correlate the parameters of perfusion MR sequence with the markers immunochemicals of tumor angiogenesis on anatomopathological specimen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitative perfusion parameters : Maximum of enhancement (Rmax (%))</measure>
    <time_frame>Day 1 at inclusion</time_frame>
    <description>Correlate the parameters of perfusion MR sequence with the markers immunochemicals of tumor angiogenesis on anatomopathological specimen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitative perfusion parameters : Timing of Maximum of enhancement (RmaxTiming (sec))</measure>
    <time_frame>Day 1 at inclusion</time_frame>
    <description>Correlate the parameters of perfusion MR sequence with the markers immunochemicals of tumor angiogenesis on anatomopathological specimen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitative perfusion parameters : Wash-inrate (WIR (%/sec)</measure>
    <time_frame>Day 1 at inclusion</time_frame>
    <description>Correlate the parameters of perfusion MR sequence with the markers immunochemicals of tumor angiogenesis on anatomopathological specimen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlate diffusion MRI parameters with immunochemical markers of tumor angiogenesis on anatomopathological specimen Quantitative diffusion parameter : Apparent Coefficient Diffusion</measure>
    <time_frame>Day 1 at inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the reduction in the time required to acquire and interpret the new breast MR protocol compared to the standard one</measure>
    <time_frame>Day 1 at inclusion</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Patient with an injected breast MR exam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MRI sequence</intervention_name>
    <description>The MR sequences added to the protocol are dedicated sequences for perfusion and diffusion imaging of breast lesion.</description>
    <arm_group_label>Patient with an injected breast MR exam</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patient&#xD;
&#xD;
          -  Patient who has signed a consent form to participate in the study&#xD;
&#xD;
          -  Affiliated patient or beneficiary of a social security scheme&#xD;
&#xD;
          -  Patient with an injected breast MR exam planned as part of her care pathway.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients under guardianship or curatorship&#xD;
&#xD;
          -  Pregnant or breastfeeding patients&#xD;
&#xD;
          -  Patients with contraindications to realization of an MR exam and an injected MR exam&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Isabelle THOMASSIN-NAGGARA, PU-PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <removed_countries>
    <country>France</country>
  </removed_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 24, 2019</study_first_submitted>
  <study_first_submitted_qc>July 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2019</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MRI</keyword>
  <keyword>breast</keyword>
  <keyword>cancer</keyword>
  <keyword>screening</keyword>
  <keyword>innovative sequences</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

